23. November 2020
Pharmaceutical patent law – 2 von 2 Insights
Which extraordinary regulations have been put in place for speeding up clinical trials in emergency situations like the current coronavirus pandemic? And how is early access to new medicines warranted under such circumstance?
The second part of the two-part series ‘Pharmaceutical Patent Law in Times of Crisis: A Comparative Study’, written for the European Intellectual Property Review by our international team, addresses these questions and more on both a broad, European level and from the perspective of six national jurisdictions.9. November 2020
von mehreren Autoren
23. November 2020
von mehreren Autoren
We explain the 5 biggest pitfalls
von Dr. Anja Lunze, LL.M. und Tobias Baus, LL.M., Dipl.-Ing.
von Dr. Anja Lunze, LL.M. und Dr. Nora E. Wessendorf, LL.M. (Washington)